Ebi Lyrics

Recent Ebi News:
Eleven Biotherapeutics Presents Data on EBI-005, a Novel IL-1 Inhibitor Protein Therapeutic for Topical Treatment of ... - Wed, 08 May 2013
Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 signaling inhibitor designed for topical ocular administration, at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting in Seattle, Washington.
La Vuelta de EBI - Sun, 19 May 2013
Join three-time U.S. National Champion, seven-time Tour de France rider, and former Olympian "Fast Freddie" Rodriguez, as Escuela Bilingüe Internacional (EBI) host their 2nd Annual "La Vuelta de EBI." Join amateurs and professionals for a morning of good health, beautiful scenery, and perhaps at times, blissful misery, as you ride along some of the East Bay's most scenic roads to conquer either ...
Eleven Biotherapeutics to Present Data on Lead Drug Candidate, EBI-005, at the ARVO 2013 Annual Meeting - Wed, 24 Apr 2013
Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics for the treatment of ocular diseases, announced today that three poster presentations on its lead drug candidate EBI-005 have been selected for presentation at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting taking place May 5-9, 2013, in Seattle, WA.
Employment Background Investigations, Inc. (EBI) Commits to Advancing Global Standards in International Background ... - Sat, 20 Apr 2013
Employment Background Investigations, Inc. (EBI) (http://www.ebiinc.com) announces its commitment to advance efforts for the expansion of standardized international background screening practices through its leadership on the NAPBS International Committee.Arlington, VA (PRWEB) April 17, 2013 NAPBS Mid-Year Legislative Conference, Arlington, VA - April 16, 2013 - Employment Background ...
Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting - Wed, 08 May 2013
Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting in Seattle ...